NCT07452601 2026-03-05
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
Tang-Du Hospital
Phase 2 Not yet recruiting
Clinical Trials
14 trialsNCT07317609 2026-01-05
Endosurgery-02
Shanghai Zhongshan Hospital
Phase 1 Recruiting
NCT06446726 2025-06-06
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2 Recruiting
NCT06861894 2025-05-15
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06861777 2025-03-11
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Not yet recruiting
NCT06388135 2024-04-29
Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Xijing Hospital
Phase 4 Not yet recruiting
NCT06178211 2023-12-20
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06173986 2023-12-18
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital
Phase 1/2 Recruiting
NCT03964753 2023-10-10
NTNC
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT05984342 2023-08-09
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
Affiliated Cancer Hospital of Shantou University Medical College
Phase 1 Recruiting
NCT05896787 2023-06-09
Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT04390958 2022-03-15
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
ChineseAMS
Phase 2 Unknown
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT02033538 2015-03-05
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus
Zhejiang University
Phase 2 Withdrawn